Regulators Endorsed Digital Twins for Clinical Trials
New guidance in the U.S. and China enables the use of virtual patients to simulate treatment outcomes in drug development.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Do you trust AI-generated medical simulations to predict treatment outcomes for human patients?
Regulatory bodies in the United States and China have issued new guidelines supporting the use of virtual patient models to inform clinical trial decisions. This shift has prompted increased demand from hospitals and pharmaceutical firms for systems that can simulate physiological responses to new drugs.
Why it matters
The adoption of digital twins offers a path to lower research costs and more predictive clinical decision-making. By integrating virtual modeling, developers can now simulate treatment evolution, accelerating a shift toward model-informed drug development.
Digital twin systems use large language models to integrate patient health data, pathology reports, and genetic sequences into unified physiological trajectories. These models perform simulations of condition evolution under varied treatment scenarios to assist in clinical decision-making.
The players
U.S. Food and Drug Administration
The federal agency overseeing drug safety and efficacy that recently moved to allow model-informed drug development.
China's National Medical Products Administration
The national regulatory body that issued new guidance encouraging the use of virtual patients to optimize medical treatments.
Qilu Hospital of Shandong University
A major teaching hospital that has initiated the procurement of a digital twin clinical trial system for approximately CNY 2.6 million.
The details
Digital twin technology functions by mapping a patient’s disparate health records into a singular, dynamic physiological profile. These virtual models act as testbeds that simulate how a condition might evolve when subjected to different pharmaceutical interventions. By analyzing these digital simulations, researchers aim to optimize treatment plans before testing them on human subjects, effectively creating a predictive environment for trial management.
Timeline
In 2025, China recorded nearly 3,000 new drug clinical trials.
During June 2026, regulators in the U.S. and China issued new guidelines for virtual patients.
From August through September 2026, modeling firms saw a spike in client requests.
The Tech Race
The formalization of model-informed drug development by the FDA marks a significant departure from traditional trial methodologies that rely exclusively on physical cohorts. This transition sets the stage for a race to secure clinical data as firms compete to capture an estimated 20 percent of the future trial market share.
While the technology is currently being procured by large hospitals and research organizations, it marks a shift toward faster drug validation cycles. Future adoption will depend on whether firms can secure the large-scale patient datasets required to make these virtual models accurate enough for regulatory approval.
The takeaway
The move toward digital twins signals a transition in how medical breakthroughs are validated, effectively lowering the cost of human-trial failure. Watch for the rollout of the Qilu Hospital system as a key benchmark for the efficacy of these models in real-world clinical environments.
Further reading
For broader trends in simulation-based medicine, explore the Biotech section.
Source note: This article includes information reported by Yicaiglobal.
Live Poll
Do you trust AI-generated medical simulations to predict treatment outcomes for human patients?
